ijms-logo

Journal Browser

Journal Browser

Molecular Advances in Haematological Malignancies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 3472

Special Issue Editors


E-Mail Website
Guest Editor
Department of Haematology, Mater Misericordiae University Hospital, D07 KH4C Dublin, Ireland
Interests: multiple myeloma; haematological malignancies; mechanisms of resistance; targeted therapies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Haematological malignancies are a broad category of cancers of the hematopoietic system, including leukaemias, lymphomas, multiple myeloma, myeloproliferative neoplasias, and myelodysplastic syndromes. The mechanism by which haematological malignancies such as leukaemia, lymphoma, and myeloma develop and proliferate in vivo is not yet fully understood. Treatment approaches, in addition to allogeneic hematopoietic stem cell transplantation, include single- and bispecific-molecule targeted therapy, such as with CAR-T cells.

This Special Issue focuses on molecular advances in the treatment of haematological malignancies and specifically welcomes original articles and review articles covering critical signalling pathways, host immune responses, pathogenesis, and novel targeted therapies such as chemotherapy, immunotherapy, stem cell transplant, monoclonal antibodies, and CAR-T cells.

Dr. Despina Bazou
Dr. Paul Dowling 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • haematological malignancies
  • multiple myeloma
  • biomarkers
  • tumour microenvironment
  • genomics
  • proteomics
  • extramedullary myeloma
  • therapy
  • minimal residual disease
  • smouldering myeloma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 4950 KiB  
Article
Network Analysis of miRNA and Cytokine Landscape in Human Hematopoiesis
by Alessandro Vici, Germana Castelli, Federica Francescangeli, Annamaria Cerio, Elvira Pelosi, Maria Screnci, Stefania Rossi, Ornella Morsilli, Nadia Felli, Luca Pasquini, Giuseppina Ivana Truglio, Maria Laura De Angelis, Vito D’Andrea, Rachele Rossi, Paola Verachi, Frenki Vila, Giovanna Marziali, Alessandro Giuliani and Ann Zeuner
Int. J. Mol. Sci. 2024, 25(22), 12305; https://doi.org/10.3390/ijms252212305 - 16 Nov 2024
Viewed by 340
Abstract
The differentiation/maturation trajectories of different blood cell types stemming from a CD34+ common ancestor takes place in different biologically relevant multidimensional spaces. Here, we generated microRNA and cytokine profiles from highly purified populations of hematopoietic progenitors/precursors derived from cord blood hematopoietic stem/progenitor [...] Read more.
The differentiation/maturation trajectories of different blood cell types stemming from a CD34+ common ancestor takes place in different biologically relevant multidimensional spaces. Here, we generated microRNA and cytokine profiles from highly purified populations of hematopoietic progenitors/precursors derived from cord blood hematopoietic stem/progenitor cells. MicroRNA and cytokine landscapes were then analyzed to find their mutual relationships under the hypothesis that the highly variable miRNome corresponds to the ‘force field’ driving the goal of a stable phenotype (here corresponding to the cytokine abundance pattern) typical of each cell kind. The high dimensionality and lack of linearity of the hematopoietic process pushed us to adopt a distance–geometry approach to compare different trajectories, while a complex network analysis was instrumental in revealing the fine structure of microRNA–cytokine relations. Importantly, the approach enabled us to identify a limited number of factors (represented either by microRNAs or cytokines) corresponding to crucial nodes responsible for connecting distinct interaction modules. Subtle changes in ‘master nodes’, keeping the connections between different regulatory networks, may therefore be crucial in influencing hematopoietic differentiation. These findings highlight the extremely interconnected network structures underlying hematopoiesis regulation and identify key factors in the microRNA/cytokine landscape that may be potentially crucial for influencing network stability. Full article
(This article belongs to the Special Issue Molecular Advances in Haematological Malignancies)
Show Figures

Figure 1

15 pages, 1730 KiB  
Article
Chimerism Testing by Next Generation Sequencing for Detection of Engraftment and Early Disease Relapse in Allogeneic Hematopoietic Cell Transplantation and an Overview of NGS Chimerism Studies
by Abdelhamid Liacini, Gaurav Tripathi, Amanda McCollick, Christopher Gravante, Peter Abdelmessieh, Yuliya Shestovska, Leena Mathew and Steven Geier
Int. J. Mol. Sci. 2023, 24(14), 11814; https://doi.org/10.3390/ijms241411814 - 23 Jul 2023
Cited by 4 | Viewed by 2715
Abstract
Chimerism monitoring after allogenic Hematopoietic Cell Transplantation (allo-HCT) is critical to determine how well donor cells have engrafted and to detect relapse for early therapeutic intervention. The aim of this study was to establish and detect mixed chimerism and minimal residual disease using [...] Read more.
Chimerism monitoring after allogenic Hematopoietic Cell Transplantation (allo-HCT) is critical to determine how well donor cells have engrafted and to detect relapse for early therapeutic intervention. The aim of this study was to establish and detect mixed chimerism and minimal residual disease using Next Generation Sequencing (NGS) testing for the evaluation of engraftment and the detection of early relapse after allo-HCT. Our secondary aim was to compare the data with the existing laboratory method based on Short Tandem Repeat (STR) analysis. One hundred and seventy-four DNA specimens from 46 individuals were assessed using a commercially available kit for NGS, AlloSeq HCT NGS (CareDx), and the STR-PCR assay. The sensitivity, precision, and quantitative accuracy of the assay were determined using artificially created chimeric constructs. The accuracy and linearity of the assays were evaluated in 46 post-transplant HCT samples consisting of 28 levels of mixed chimerism, which ranged from 0.3–99.7%. There was a 100% correlation between NGS and STR-PCR chimerism methods. In addition, 100% accuracy was attained for the two external proficiency testing surveys (ASHI EMO). The limit of detection or sensitivity of the NGS assay in artificially made chimerism mixtures was 0.3%. We conducted a review of all NGS chimerism studies published online, including ours, and concluded that NGS-based chimerism analysis using the AlloSeq HCT assay is a sensitive and accurate method for donor-recipient chimerism quantification and minimal residual disease relapse detection in patients after allo-HCT compared to STR-PCR assay. Full article
(This article belongs to the Special Issue Molecular Advances in Haematological Malignancies)
Show Figures

Figure 1

Back to TopTop